Composition for inhalation

Abstract

The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.

1 . A pharmaceutical composition comprising formoterol, budesonide, HFA 227, PVP and PEG. 
     
     
         2 . A formulation according to  claim 1  characterised in that the PVP is present from about 0.0005 to about 0.05% w/w and the PEG is present from about 0.05 to about 0.35% w/w. 
     
     
         3 . A pharmaceutical composition according to  claim 1  in which the PVP is PVP K25. 
     
     
         4 . A pharmaceutical composition according to  claims 1  in which the PVP is present in an amount of 0.001% w/w. 
     
     
         5 . A pharmaceutical composition according to  claim 1  in which the PEG is PEG 1000. 
     
     
         6 . A pharmaceutical composition according to  claim 1  in which the PEG is present in an amount of 0.3% w/w. 
     
     
         7 . A pharmaceutical composition according to  claim 1  in which formoterol is in the form of its fumarate dihydrate salt. 
     
     
         8 . A pharmaceutical composition according to  claim 1  in which the formoterol is in the form of the single R, R-enantiomer. 
     
     
         9 . A pharmaceutical composition according to  claim 1  in which the second active ingredient is the 22R-epimer of budesonide. 
     
     
         10 . A pharmaceutical composition according to  claim 1  for use for the treatment or prophylaxis of a respiratory disorder. 
     
     
         11 . A pharmaceutical composition according to  claim 1  for use for the treatment or prophylaxis of asthma, rhinitis or COPD. 
     
     
         12 . A method of treating a respiratory disorder in a mammal which comprises administering to a patient a pharmaceutical composition according to  claim 1 .